A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza białaczki limfocytowej (CLL/SLL), która wcześniej nie była leczona i wymaga rozpoczęcia leczenia
- •Wiek 18 lat lub więcej
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG 0-2)
- •Prawidłowa funkcja wątroby - wyszczególnione wartości bilirubiny, ALT i AST
- •Prawidłowa funkcja nerek - wartość clearance'u kreatyniny co najmniej 50 mL/min
- •Prawidłowa liczba płytek krwi (≥50), hemoglobiny (≥8 g/dL) i neutrofili (≥0.75)
- •Prawidłowe parametry krzepnięcia krwi
- •Zdolność do połykania tabletek i regularnego uczestniczenia w wizytach i badaniach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UT MD Anderson
Houston, United States
Trial contact
Nitin Jain, MBBS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.